Education
About Us
Working with TipRanks
Follow Us
Osteopore Ltd. (AU:OSX)
ASX:OSX
OSX Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.05
Previous CloseN/A
Volume70.28K
Average Volume (3M)2.16M
Market Cap
AU$3.86M
Enterprise ValueAU$2.16M
Total Cash (Recent Filing)AU$1.81M
Total Debt (Recent Filing)AU$1.68M
Price to Earnings (P/E)―
Beta4.74
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding482,501,800
10 Day Avg. Volume675,672
30 Day Avg. Volume2,156,422
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.95
Price to Sales (P/S)0.97
P/FCF Ratio-0.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent high revenue growth (26.8% in 2024) indicates increasing clinical adoption of Osteopore’s implants and expanding market reach. Durable top-line expansion can allow the company to scale fixed costs, improve operating leverage, and fund commercialization across indications if sustained.
Gross MarginVery strong gross margins (>84%) reflect product-level pricing power and/or low direct manufacturing cost for 3D‑printed scaffolds. Sustained high gross margins provide structural capacity to cover R&D and SG&A, improving prospects for operating profitability as volumes scale.
Product Differentiation / Market NicheOsteopore’s focus on 3D‑printed bioresorbable implants targets regenerative surgery niches with durable clinical need (craniofacial, orthopedics). The specialized technology and clinical application create structural differentiation and a moat vs commodity implants, supporting long-term adoption.
Bears Say
ProfitabilityOngoing negative EBIT and net losses indicate the business has yet to achieve operating leverage over costs. Persistent unprofitability constrains reinvestment, increases reliance on external capital, and raises execution risk until scale or cost structure improvements translate to sustainable profits.
Cash Flow / Cash BurnConsistent negative operating and free cash flows signal structural cash burn from operations. This forces dependence on financing for working capital and growth, limits strategic flexibility, and increases refinancing or dilution risk if cash generation does not improve within the medium term.
Leverage / Balance Sheet RiskDebt exceeding equity and a falling equity ratio indicate elevated financial leverage. Higher leverage amplifies interest and liquidity risk, reduces resilience to revenue shocks, and can constrain investment or M&A options unless deleveraging or stronger cash generation occurs.
Osteopore Ltd. News
OSX FAQ
What was Osteopore Ltd.’s price range in the past 12 months?
Osteopore Ltd. lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Osteopore Ltd.’s market cap?
Osteopore Ltd.’s market cap is AU$3.86M.
When is Osteopore Ltd.’s upcoming earnings report date?
Osteopore Ltd.’s upcoming earnings report date is Feb 27, 2026 which is in 5 days.
How were Osteopore Ltd.’s earnings last quarter?
Osteopore Ltd. released its earnings results on Aug 29, 2025. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Osteopore Ltd. overvalued?
According to Wall Street analysts Osteopore Ltd.’s price is currently Overvalued.
Does Osteopore Ltd. pay dividends?
Osteopore Ltd. does not currently pay dividends.
What is Osteopore Ltd.’s EPS estimate?
Osteopore Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Osteopore Ltd. have?
Osteopore Ltd. has 482,501,800 shares outstanding.
What happened to Osteopore Ltd.’s price movement after its last earnings report?
Osteopore Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Osteopore Ltd.?
Currently, no hedge funds are holding shares in AU:OSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Osteopore Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.79%
12-Months-Change
Fundamentals
Return on Equity
-487.52%
Trailing 12-Months
Asset Growth
-7.78%
Trailing 12-Months
Company Description
Osteopore Ltd.
Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications in Singapore, Australia, and internationally. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; and Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects. Osteopore Limited has a collaboration agreement with Livingstone Health Holding Limited to jointly develop new applications and products for regenerating bone and tissue. The company was incorporated in 2003 and is headquartered in Singapore.
Technical Analysis
Orthocell Ltd
―
Aroa Biosurgery Ltd
―
ImExHS Limited
―
Emyria Ltd
―
Arovella Therapeutics Limited
―